Division of Vitreoretinal Surgery, Charles Retina Institute, Memphis, Tennessee; Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, Tennessee.
Division of Vitreoretinal Surgery, Charles Retina Institute, Memphis, Tennessee; Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, Tennessee.
Surv Ophthalmol. 2014 Jan-Feb;59(1):30-46. doi: 10.1016/j.survophthal.2013.03.007. Epub 2013 Oct 15.
Since its original description in 1908, Coats disease has been recognized as an idiopathic cause of severe vision loss with a remarkable diversity in clinical presentation and morphology. Key clinical and imaging variables are helpful in differentiating Coats disease from life-threatening malignancies, and proper management revolves around a thorough knowledge of the differential diagnosis. Despite significant advancement in scientific understanding of the disease process and clinical spectrum, the underlying etiology remains obscure, and both primary and secondary forms are recognized. With the development of anti-VEGF therapy, vitreoretinal specialists have a new, effective adjunct to the clinical management of exudates, macular edema, and serous retinal detachment. We highlight the history, diagnostic challenges, evolving clinical spectrum, and current management of Coats disease.
自 1908 年首次描述以来,Coats 病已被认为是一种特发性疾病,可导致严重视力丧失,其临床表现和形态学变化显著。关键的临床和影像学变量有助于将 Coats 病与危及生命的恶性肿瘤区分开来,适当的治疗方法围绕着对鉴别诊断的深入了解。尽管对疾病过程和临床谱的科学理解有了显著进展,但潜在病因仍不清楚,并且已经认识到原发性和继发性两种形式。随着抗血管内皮生长因子治疗的发展,玻璃体视网膜专家对渗出物、黄斑水肿和浆液性视网膜脱离的临床管理有了新的、有效的辅助手段。我们重点介绍 Coats 病的历史、诊断挑战、不断发展的临床谱和当前的治疗方法。